In-vitro Anticancer Activity of Copper (II) and Zinc (II) Complexes with Derived Schiff Base Ligands
In-vitro Anticancer Activity of Copper (II) and Zinc (II) Complexes with Derived Schiff Base Ligands
Qaisar Jamal1,Salman Ahmad1, Nazma Habib Khan1, Sobia Wahid1, Muhammad Ikram2, Sadia Rehman2, Syed Basit Rasheed1 and Akram Shah1,*
ABSTRACT
Derivatives of Schiff bases have been considerably screened for their anticancer potential. We aimed to investigate in-vitro anticancer activity of two transition metal compounds of derived Schiff bases; NM-3 (Tetrakis (2-{(E)-[(2- {[(Z)-(2-hydroxynapthyl) methylidene]amino} phenyl)imino] methyl}phenol) Copper(II) and NM-4 (Tetrakis (2-{(E)-[(2- {[(Z)-(2-hydroxynapthyl) methylidene] amino}phenyl)imino]methyl} phenol) zinc(II)), against human THP-1 leukemia cell line in-relation to miltefosine (standard chemotherapy). Mean % inhibition for NM-3 against THP-1 was higher than NM-4, although both were less effective than miltefosine. IC50 for miltefosine, NM-3 and NM-4 against THP-1was 0.000347µM, 44.9µM and 119µM; whereas, their cytotoxicity was 72.26µM, 255µM and 293.8µM, respectively against peripheral blood lymphocytes. Based on the findings of present study the compounds can be put in to list of candidacy for anticancer activity.
To share on other social networks, click on any share button. What are these?
December 2018
Vol. 50, Iss. 6, Pages 1999-2398
